Send to

Choose Destination
Clin Infect Dis. 2011 Jun;52 Suppl 7:S504-12. doi: 10.1093/cid/cir174.

Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.

Author information

Cempra Pharmaceuticals Inc., Chapel Hill, North Carolina 27517, USA.


A phase 1 trial of fusidic acid (CEM-102), an oral fusidane class antibiotic under development for treatment of gram-positive acute bacterial skin and skin structure infections, evaluating pharmacokinetics and safety is described. A randomized, double-blinded, placebo-controlled, dose escalation study was conducted in healthy adult subjects in the fasting state. Plasma exposure after multiple doses was higher than for single doses, indicating accumulation. Loading doses designed to optimize pharmacodynamic effects were well tolerated and achieved near-steady state concentrations of CEM-102 at 24 h. CEM-102 was safe and generally well tolerated at all single, multiple, and loading doses administered.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center